Literature DB >> 10921996

Two successive hepatitis C virus infections in an intravenous drug user.

B Proust1, F Dubois, Y Bacq, S Le Pogam, S Rogez, R Levillain, A Goudeau.   

Abstract

We report the case of an occasional intravenous drug user who developed two successive hepatitis C virus (HCV) infections. The first infection led to seroconversion (anti-HCV antibodies detected) and the detection of HCV RNA in serum. After a spontaneous recovery (normalization of alanine aminotransferase levels and HCV RNA clearance), a second HCV infection was observed, with the recurrence of HCV viremia. Antibody directed against HCV serotype 1 was detected throughout the follow-up monitoring, but two different HCV strains were identified during the two infectious episodes: genotype 1a for the first and genotype 3a for the second. This observation shows that primary HCV infection does not confer protective immunity against subsequent infection with viruses of other genotypes. This may hamper the development of a vaccine. Conflicting results were obtained in genotyping and serotyping assays, suggesting that the serotyping method cannot be used to identify the HCV type in patients, such as intravenous drug users, who are exposed to successive HCV infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10921996      PMCID: PMC87209     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections.

Authors:  G Kuno; D J Gubler; A Oliver
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Jan-Feb       Impact factor: 2.184

2.  Typing of hepatitis C virus antibody with specific peptides in seropositive blood donors and comparison with genotyping of viral RNA.

Authors:  P León; J A López; C Elola; S Quan; J M Echevarría
Journal:  Vox Sang       Date:  1997       Impact factor: 2.144

3.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.

Authors:  H M Diepolder; R Zachoval; R M Hoffmann; E A Wierenga; T Santantonio; M C Jung; D Eichenlaub; G R Pape
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

4.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

Authors:  M Martinot-Peignoux; P Marcellin; M Pouteau; C Castelnau; N Boyer; M Poliquin; C Degott; I Descombes; V Le Breton; V Milotova
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

5.  HLA-DR5 antigen. A genetic factor influencing the outcome of hepatitis C virus infection?

Authors:  G Peano; G Menardi; A Ponzetto; L M Fenoglio
Journal:  Arch Intern Med       Date:  1994 Dec 12-26

6.  Immunity in hepatitis C infection.

Authors:  A M Prince; B Brotman; T Huima; D Pascual; M Jaffery; G Inchauspé
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

7.  Lack of protective immunity against reinfection with hepatitis C virus.

Authors:  P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

8.  Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children.

Authors:  M E Lai; A P Mazzoleni; F Argiolu; S De Virgilis; A Balestrieri; R H Purcell; A Cao; P Farci
Journal:  Lancet       Date:  1994-02-12       Impact factor: 79.321

9.  Disquisitions of Original Antigenic Sin. I. Evidence in man.

Authors:  R G Webster
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

10.  Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus.

Authors:  F M DAVENPORT; A V HENNESSY; T FRANCIS
Journal:  J Exp Med       Date:  1953-12       Impact factor: 14.307

View more
  20 in total

1.  Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance.

Authors:  Matthias Schröter; Bernhard Zöllner; Peter Schäfer; Andreas Reimer; Matthias Müller; Rainer Laufs; Heinz-Hubert Feucht
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

2.  Written in response to Scott LD: treating hepatitis C in active injection drug users.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Am J Gastroenterol       Date:  2005-09       Impact factor: 10.864

3.  Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity.

Authors:  A J Weiner; X Paliard; M J Selby; A Medina-Selby; D Coit; S Nguyen; J Kansopon; C L Arian; P Ng; J Tucker; C T Lee; N K Polakos; J Han; S Wong; H H Lu; S Rosenberg; K M Brasky; D Chien; G Kuo; M Houghton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup.

Authors:  Catherine Gaudy; Catherine Thevenas; Jean Tichet; Nicole Mariotte; Alain Goudeau; Frédéric Dubois
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

5.  Managing Hepatitis C in Users of Illicit Drugs.

Authors:  Brian R Edlin; Michael R Carden; Stephen J Ferrando
Journal:  Curr Hepat Rep       Date:  2007

6.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 7.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Authors:  Brian R Edlin; Thomas F Kresina; Daniel B Raymond; Michael R Carden; Marc N Gourevitch; Josiah D Rich; Laura W Cheever; Victoria A Cargill
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

8.  Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses.

Authors:  Brendan A Palmer; Daniel Schmidt-Martin; Zoya Dimitrova; Pavel Skums; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

9.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

10.  Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Authors:  Julian Schulze Zur Wiesch; Georg M Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Andrea M Jones; Brian E Nolan; Steve A Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W Lohse; Lia L Lewis-Ximenez; Raymond T Chung; Arthur Y Kim; Todd M Allen; Bruce D Walker
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.